Hevicain Spinal Tung

Hevicain Spinal Tung is a prescription intrathecal formulation containing the local anesthetic bupivacaine hydrochloride. Marketed in the European Union, this product delivers the active ingredient in a sterile solution intended for spinal anesthesia. As a member of the amide-type local anesthetic class, it provides reversible nerve block when administered into the cerebrospinal fluid. The preparation is supplied without a fixed strength label, and it must be used under professional supervision.

Hevicain Spinal Tung is indicated for use in procedures that require spinal anesthesia, providing a reliable block of sensory and motor function in the lower body.

- Induction of surgical anesthesia for lower abdominal, pelvic, or lower limb operations. - Facilitation of obstetric procedures such as cesarean delivery when spinal anesthesia is preferred. - Provision of anesthesia for urological or orthopedic surgeries involving the lower extremities. - Use in diagnostic or therapeutic interventions that require temporary loss of sensation in the lower trunk. - Adjunct to combined spinal-epidural techniques for extended analgesia.

Adverse reactions to Hevicain Spinal Tung are generally related to its local anesthetic properties and the intrathecal route of administration.

Common: - Transient hypotension or bradycardia during the early phase after injection. - Temporary motor weakness or inability to move the lower limbs. - Mild pruritus or skin itching at the injection site. - Nausea or vomiting associated with sympathetic blockade.

Serious: - High spinal block leading to respiratory compromise. - Cardiac arrhythmias or severe hypotension unresponsive to standard measures. - Neurological deficits such as persistent paresthesia or cauda‑equina syndrome. - Allergic reactions including urticaria, angioedema, or anaphylaxis.

When using Hevicain Spinal Tung, clinicians should observe several precautionary measures to reduce the risk of complications.

- Assess cardiovascular status; patients with severe hypotension or heart block may be at increased risk. - Evaluate for contraindications such as infection at the puncture site or known hypersensitivity to amide local anesthetics. - Use the lowest effective dose and monitor hemodynamic parameters continuously during and after injection. - Consider the potential for high spinal spread in pregnant or obese patients and adjust positioning accordingly. - Ensure availability of resuscitation equipment and agents to treat severe hypotension or respiratory depression. - Review concomitant medications that may potentiate bupivacaine toxicity, such as other sodium channel blockers.

Hevicain Spinal Tung may interact with other agents that influence cardiac conduction, systemic anesthetic depth, or metabolic clearance.

Avoid: - Concurrent use of other potent local anesthetics or systemic bupivacaine, which can increase toxicity risk. - Co‑administration with class I antiarrhythmic drugs (e.g., quinidine, procainamide) that also block sodium channels. - Intravenous infusion of high‑dose vasopressors that may mask hypotensive signs.

Use with caution: - Combination with opioids or sedatives administered intrathecally, as they may enhance spinal block and respiratory depression. - Patients receiving beta‑blockers or calcium channel blockers, which can potentiate bradycardia. - Use in individuals taking CYP3A4 inhibitors, which may slow bupivacaine metabolism.